Mariana Pinto

Dr. Mariana Pinto


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FFFernanda Ferreira
Fernanda Ferreira
LSLucas Eduardo Botelho Souza
Lucas Eduardo Botelho Souza
CTCarolina Thomé
Carolina Thomé
MPMariana Pinto
Mariana Pinto
COClarice Origassa
Clarice Origassa
DCDimas Tadeu Covas
Dimas Tadeu Covas
The endothelial-to-mesenchymal transition (EndMT) is a biological process where endothelial cells (ECs) acquire a fibroblastic phenotype after concomitant loss of the apical-basal polarity and intercellular junction proteins. This process is critical to embryonic development and is involved in diseases such as fibrosis and tumor progression. The signaling pathway of the transforming growth factor β (TGF-β) is an important molecular route responsible for EndMT activation. However, it is unclear whether the anatomic location of endothelial cells influences the activation of molecular pathways responsible for EndMT induction. Our study investigated the molecular mechanisms and signaling pathways involved in EndMT induced by TGF-β2 in macrovascular ECs obtained from different sources. For this purpose, we used four types of endothelial cells (coronary artery endothelial cells, CAECs; primary aortic endothelial cells PAECs; human umbilical vein endothelia cells, HUVECs; and human pulmonary artery endothelial cells, HPAECs) and stimulated with 10 ng/mL of TGF-β2. We observed that among the ECs analyzed in this study, PAECs showed the best response to the TGF-β2 treatment, displaying phenotypic changes such as loss of endothelial marker and acquisition of mesenchymal markers, which are consistent with the EndMT activation. Moreover, the PAECs phenotypic transition was probably triggered by the extracellular signal–regulated kinases 1/2 (ERK1/2) signaling pathway activation. Therefore, the anatomical origin of ECs influences their ability to undergo EndMT and the selective inhibition of the ERK pathway may suppress or reverse the progression of diseases caused or aggravated by the involvement EndMT activation.

30 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MPMariana Pinto
Mariana Pinto
GMGisele Eiras Martins
Gisele Eiras Martins
AVAna Glenda Santarosa Vieira
Ana Glenda Santarosa Vieira
JGJanaina Mello Soares Galvão
Janaina Mello Soares Galvão
CSCristiano Souza
Cristiano Souza
LLLuiz Fernando Lopes
Luiz Fernando Lopes
Ovarian germ cell tumors (OGCTs) are rare in adults; indeed, they occur predominantly in children, adolescents, and young adults, and they account for approximately 11% of cancer diagnoses in these groups. Because OGCTs are rare tumors, our current understanding of them is sparse; this is because few studies have investigated the molecular basis of pediatric and adult cancers. Here, we review the etiopathogenesis of OGCTs in children and adults, and we address the molecular landscape of these tumors, including integrated genomic analysis, microRNAs, DNA methylation, the molecular implications of treatment resistance, and the development of in vitro and in vivo models. An elucidation of potential molecular alterations may provide a novel field for understanding the pathogenesis, tumorigenesis, diagnostic markers, and genetic peculiarity of the rarity and complexity of OGCTs.

9 May 2024 in Molecular Oncology
Verified
Journal Article
Open access
AVAna Glenda Santarosa Vieira
Ana Glenda Santarosa Vieira
LSLuciane Sussuchi da Silva
Luciane Sussuchi da Silva
ESEduardo Caetano Albino da Silva
Eduardo Caetano Albino da Silva
ALAna Carolina Laus
Ana Carolina Laus
TFThaíssa Maria Veiga Faria
Thaíssa Maria Veiga Faria
MPMariana Pinto
Mariana Pinto
MicroRNAs (miRNAs) are small endogenous noncoding RNAs, and alterations in their expression may contribute to oncogenesis. Discovering a unique miRNA pattern holds the potential for early detection and novel treatment possibilities in cancer. This study aimed to evaluate miRNA expression in pediatric patients with gonadal germ cell tumors (GCTs), focusing on characterizing the miRNA profiles of each histological subtype and identifying a distinct histological miRNA signature for a total of 42 samples of pediatric gonadal GCTs. The analysis revealed distinct miRNA expression profiles for all histological types, regardless of the primary site. We identified specific miRNA expression signatures for each histological type, including 34 miRNAs for dysgerminomas, 13 for embryonal carcinomas, 25 for yolk sac tumors, and one for immature teratoma, compared to healthy controls. Furthermore, we identified 26 miRNAs that were commonly expressed in malignant tumors, with six miRNAs (miR‐302a‐3p, miR‐302b‐3p, miR‐371a‐5p, miR‐372‐3p, miR‐373‐3p, and miR‐367‐3p) showing significant overexpression. Notably, miR‐302b‐3p exhibited a significant association with all the evaluated clinical features. Our findings suggest that miRNAs have the potential to aid in the diagnosis, prognosis, and management of patients with malignant GCTs.

Verified
Journal Article
Open access
PDF file
Patrik da Silva VitalPatrik da Silva Vital
Patrik da Silva Vital
MBMurilo Bonatelli
Murilo Bonatelli
MDMarina Pereira Dias
Marina Pereira Dias
LSLarissa Vedovato Vilela de Salis
Larissa Vedovato Vilela de Salis
MPMariana Pinto
Mariana Pinto
CPCéline Pinheiro
Céline Pinheiro
(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, even with contemporary therapeutic alternatives. Highly proliferative tumors often rely on glycolysis to sustain their aggressive phenotype. 3-bromopyruvate (3BP) is a promising glycolysis inhibitor reported to mitigate resistance in tumors. This study aimed to evaluate the potential of 3BP as an antineoplastic agent for PLX-resistant melanoma treatment. (2) The effect of 3BP alone or in combination with PLX on viability, proliferation, colony formation, cell death, migration, invasion, epithelial-mesenchymal marker and metabolic protein expression, extracellular glucose and lactate, and reactive species were evaluated in two PLX-resistant melanoma cell lines. (3) 3BP treatment, which was more effective as monotherapy than combined with PLX, disturbed the metabolic and epithelial-mesenchymal profile of PLX-resistant cells, impairing their proliferation, migration, and invasion and triggering cell death. (4) 3BP monotherapy is a potent metabolic-disrupting agent against PLX-resistant melanomas, supporting the suppression of the malignant phenotype in this type of neoplasia.

20 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LSLenilson Silva
Lenilson Silva
ICIngridy Izabella Vieira Cardoso
Ingridy Izabella Vieira Cardoso
MCMarcelo Cavalcanti da Cruz
Marcelo Cavalcanti da Cruz
TFThaíssa Maria Veiga Faria
Thaíssa Maria Veiga Faria
GMGisele Eiras Martins
Gisele Eiras Martins
MPMariana Pinto
Mariana Pinto
Introduction: Pediatric germ cell tumors (GCTs) are rare malignancies, comprising only about 3% of childhood cancers. Despite surgery and platinum-based chemotherapy being mainstays of treatment, their effectiveness varies by tumor subtype, and long-term toxicities remain a concern. We therefore explored the immune landscape of pediatric GCTs to uncover subtype-specific immunological features and identify potential immunotherapeutic targets.Methods: This retrospective study investigated the immune landscape of pediatric GCTs, utilizing a cohort of 17 patients, including 14 extracranial GCTs (11 ovarian, 3 testicular), three central nervous system (CNS) mixed tumors and four non-neoplastic tissues (controls).Results: Immune profiling revealed distinct immune microenvironments across the GCT subtypes. Dysgerminomas exhibited an immune-active profile with elevated levels of T cells, CD8+ T cells, and cytotoxic cells, alongside upregulation of immune checkpoints CTLA4, TIGIT, and IDO1, suggesting potential responsiveness to checkpoint inhibitors. In contrast, yolk sac tumors displayed an immunosuppressive environment with high CD24 and PVR expression, indicative of unique immune evasion mechanisms. Embryonal carcinomas also showed high CD24 expression. An in silico analysis of adult GCTs highlighted similarities and differences with pediatric cases; IDO1 and CD24 were consistently upregulated across age groups, while CTLA4 and PVR showed variation.Conclusion: Overall, this study provides new insights into pediatric GCT immunology, supporting the potential for tailored immunotherapeutic strategies targeting the distinct immune profiles of pediatric GCT histologies.

16 February 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JGJanaina Mello Soares Galvão
Janaina Mello Soares Galvão
ABAna Flavia Souza Peres Bezerra
Ana Flavia Souza Peres Bezerra
FGFelipe Antonio De Oliveira Garcia
Felipe Antonio De Oliveira Garcia
AVAna Glenda Santarosa Vieira
Ana Glenda Santarosa Vieira
ESEduardo Caetano Albino Da Silva
Eduardo Caetano Albino Da Silva
MPMariana Pinto
Mariana Pinto
Introduction: Germ cell tumors (GCTs) are rare neoplasms affecting approximately 3.5% of all pediatric patients, with diverse histological subtypes. Despite their clinical and biological heterogeneity, pediatric GCTs generally exhibit a low mutational burden. Compared to adult GCTs, however, the molecular characterization of pediatric cases remains limited, hindering the development of targeted therapeutic strategies. Therefore, we aimed to elucidate the genomic landscape of pediatric GCT patients via whole exome sequencing (WES). Methods: WES was performed in 16 pediatric GCTs and respective matched normal samples, including ten ovarian, five testicular, and one mediastinal tumor. The somatic alterations found were described and compared with the clinicopathological characteristics, as well as related to molecular databases. Results: The somatic mutations found resemble those observed in adult GCTs and recent pediatric GCTs studies. Genes with predicted oncogenic variants were found in seven samples (43.75%) out of 16 and included KIT (12.5%), KRAS (6.25%), MTOR (12.5%), PIK3CA (6.25%), AKT2 (6.25%), LARP4B (6.25%), and ACSL6 (6.25%). Copy number alterations were identified on chromosomes 4, 7, 8, 10, 12, 21, and 22, with amplification of CDKN1B , KRAS , CCND2 , ETV6 , and KDM5A genes, and deletions of KIT and PTEN genes. Clinically significant mutations ( KIT : Asp816Val, Ala829Pro; and KRAS : Gln61Leu) suggest potential therapeutic targets for GCT, while MTOR , PIK3CA , and AKT2 emerge as candidates for targeted therapy. Discussion: These findings provide insights into the genomic alterations of pediatric GCTs and emphasize the potential for targeted therapies.